SAB Biotherapeutics, Inc. (SABS) Retained Earnings (Accumulated Deficit) USD 2020 - 2024

Historical data

Taxonomy & unit
us-gaap: USD
Description
The cumulative amount of the reporting entity's undistributed earnings or deficit.
Summary
SAB Biotherapeutics, Inc. quarterly Retained Earnings (Accumulated Deficit) history and growth rate from 2020 to 2024.
  • SAB Biotherapeutics, Inc. Retained Earnings (Accumulated Deficit) for the quarter ending March 31, 2024 was -$95.1 M, a 72.2% decline year-over-year.
Retained Earnings (Accumulated Deficit), Quarterly (USD)
Retained Earnings (Accumulated Deficit), YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q1 2024 -$95.1 M -$39.9 M -72.2% Mar 31, 2024 10-Q 2024-05-20
Q4 2023 -$90.1 M -$42.2 M -88.1% Dec 31, 2023 10-Q 2024-05-20
Q3 2023 -$67.2 M -$27.2 M -68% Sep 30, 2023 10-Q 2023-11-13
Q2 2023 -$62.1 M -$29.2 M -88.7% Jun 30, 2023 10-Q 2023-08-21
Q1 2023 -$55.2 M -$27.1 M -96.2% Mar 31, 2023 10-Q 2023-05-15
Q4 2022 -$47.9 M -$18.7 M -64.3% Dec 31, 2022 10-K 2024-03-29
Q3 2022 -$40 M -$30.7 M -330% Sep 30, 2022 10-Q 2022-11-14
Q2 2022 -$32.9 M -$24 M -267% Jun 30, 2022 10-K 2023-04-14
Q1 2022 -$28.1 M -$21.4 M -316% Mar 31, 2022 10-K 2023-04-14
Q4 2021 -$29.1 M -$17.1 M -143% Dec 31, 2021 10-K/A 2023-04-28
Q3 2021 -$9.29 M Sep 30, 2021 10-Q 2021-11-22
Q2 2021 -$8.96 M Jun 30, 2021 10-Q 2021-11-22
Q1 2021 -$6.76 M Mar 31, 2021 10-Q 2021-11-22
Q4 2020 -$12 M Dec 31, 2020 10-K/A 2023-04-28
* An asterisk sign (*) next to the value indicates that the value is likely invalid.